

## P&T Motion History Second Generation Antipsychotics

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
aripiprazole brexpiprazole cariprazine olanzapine quetiapine risperidone ziprasidone	<p><b>Atypical Antipsychotics as Adjuvant Therapy for the Treatment of MDD</b></p> <p>After considering the evidence of safety, efficacy and special populations for the Adjuvant Therapy for the Treatment of MDD, I move that aripiprazole, brexpiprazole, cariprazine, olanzapine, quetiapine, risperidone, and ziprasidone are efficacious for their approved FDA indications and should be preferred on the Washington Preferred Drug List. Second Generation Antipsychotics cannot be subject to therapeutic interchange in the Washington preferred drug list. The preferred drug list should include at least one medication that is considered safe in pregnancy.</p> <p>Motion: Beste 2<sup>nd</sup>: Barkett</p>	April 17, 2024	NA	No	Passed unanimous

**Bold** = new this update

Grey = not reviewed or not part of WA PDL drug class

\*=drugs not reviewed, but carried forward from previous review

5/6/2024